News and Events

Lasting benefits of pembrolizumab

11 August 2017

According to the results of a phase III clinical trial reported at ASCO 2017, “pembrolizumab (anti-PD-1) provided lasting benefits in patients with advanced melanoma, and was associated with a relatively low (9%) risk of disease progression or death almost a year after finishing treatment”. 

Whangarei Common Skin Lesions and Dermatoscopy Course

10 August 2017

Conducted by Honorary Associate Professor Amanda Oakley, this one-day course will address clinical and dermatoscopic diagnosis of common benign and malignant skin lesions, particularly pigmented lesions.

Sentinel lymph node a gateway for metastasis

2 August 2017

Results of this study suggest that progression of disease from the sentinel lymph node (SLN) to the non-SLN compartment is orderly and is associated with the worsening of the disease status.

Photoaging mobile apps hold promise for behaviour change

1 August 2017

The authors of this study conclude that “based on previous studies and the initial study results presented here, it is reasonable to speculate that the app may induce behavioural change in the target population".

Melanoma and Parkinson’s disease link

23 July 2017

Patients with Parkinson's disease (PD) have about a 4-fold increased risk of having pre-existing melanoma and those with melanoma have a similar risk of developing PD, according to new retrospective, case-control analyses.

No reduction in sunbed use with under 18 year ban

18 July 2017

Findings of a study among Irish teenagers found that there was no reduction of sunbed use in teenagers two years after the introduction of legislation banning its use in those aged < 18 years.